Fusion to open radiopharmaceutical manufacturing facility

Fusion Pharmaceuticals announced the opening of its state-of-the-art radiopharmaceutical manufacturing facility. The 27,000 square foot good manufacturing practice, or GMP, compliant facility, which is located adjacent to the Company’s research and development labs, has clinical and commercial manufacturing scale capabilities designed to support the Company’s growing pipeline of targeted alpha therapies, or TATs. The new manufacturing facility, part of a 15-year lease agreement with Hamilton, Ontario-based McMaster University, was built by McMaster and equipped and validated by Fusion. At full capacity, it is expected to produce more than 100,000 doses of TATs per year. Fusion Pharmaceuticals is a spin out company of the Centre for Probe Development and Commercialization hosted at McMaster and founded by Dr. Valliant, who is also a McMaster chemistry professor.